{"filing":{"accession_number":"0001193125-26-397870","cik":"0001840439","ticker":"BMEA","company_name":"Biomea Fusion, Inc.","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"bmea-20260922.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840439/000119312526397870/bmea-20260922.htm"},"events":[{"id":34291,"run_id":31558,"accession_number":"0001193125-26-397870","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Biomea Fusion disclosed an update to the anticipated timing of topline results from its Phase I GLP-131 trial for BMF-650, now expected in October 2026. This is a material clinical trial milestone update for a biopharmaceutical company, representing progress toward regulatory and commercial objectives. While not fitting a specific named event type, this operational/strategic disclosure affects investor assessment of the company's pipeline and development trajectory.","company_name":"Biomea Fusion, Inc.","ticker":"BMEA","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":37974,"accession_number":"0001193125-26-397870","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Biomea Fusion disclosed an update to the anticipated timing of topline results from its Phase I GLP-131 trial for BMF-650, now expected in October 2026. This is a material clinical trial milestone update for a biopharmaceutical company, representing progress toward regulatory and commercial objectives. While not fitting a specific named event type, this operational/strategic disclosure affects investor assessment of the company's pipeline and development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:03:49.522765+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37974,"accession_number":"0001193125-26-397870","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Biomea Fusion disclosed an update to the anticipated timing of topline results from its Phase I GLP-131 trial for BMF-650, now expected in October 2026. This is a material clinical trial milestone update for a biopharmaceutical company, representing progress toward regulatory and commercial objectives. While not fitting a specific named event type, this operational/strategic disclosure affects investor assessment of the company's pipeline and development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:03:49.522765+00:00","company_name":"Biomea Fusion, Inc.","ticker":"BMEA","filing_date":"2026-09-22"}]}